• 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337(24): 17331745.
  • 2
    Chen G, Lin W, Shen F et al. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol 2005; 34(1): 132137.
  • 3
    Zhiqiang G, Zhaohui D, Qinhuan W et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004; 38(10 Suppl. 3): S175S178.
  • 4
    Yao GB. Treatment of chronic hepatitis B in China. J Gastroenterol Hepatol 2000; 15(Suppl.): E61E66.
  • 5
    Beasley RP, Hwang LY, Lin CC et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2(8256): 11291133.
  • 6
    Lesmana LA, Leung NW, Mahachai V et al. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Int, 2006; 26(S2): 310.
  • 7
    Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35(5): 12741276.
  • 8
    Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – large-scale analysis using a new genotyping method. J Infect Dis 1997; 175(6): 12851293.
  • 9
    Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12(2): 111124.
  • 10
    Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 26822695.
  • 11
    Gao R, Liao Z, Li ZS. Scientific publications in gastroenterology and hepatology journals from Chinese authors in various parts of North Asia: 10-year survey of literature. J Gastroenterol Hepatol 2008; 23(3): 374378.
  • 12
    Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J (Engl) 2007; 120(24): 21572158.
  • 13
    Data on 2006 seroepidemiological survery on HBV infection in China. Released by Ministry of Health of the People’s Republic of China.
  • 14
    Chen B, Chen H, Lacey L et al. Cost effectiveness of lamivudine treatment for patients with chronic hepatitis B. Chin Hepatol (Chin) 2002; 7(2): 7981.
  • 15
    Zeng G, Wang Z, Wen S et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005; 12(6): 609617.
  • 16
    Ding X, Mizokami M, Yao G et al. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 2001; 44(1): 4347.
  • 17
    Ding X, Mizokami M, Ge X et al. Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, southern China. Hepatol Res 2002; 22(1): 3744.
  • 18
    Xia G, Nainan OV, Jia Z. [Characterization and distribution of hepatitis B virus genotypes and subtypes in 4 provinces of China]. Zhonghua Liu Xing Bing Xue Za Zhi 2001; 22(5): 348351.
  • 19
    Wang Z, Liu Z, Zeng G et al. A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China. J Gen Virol 2005; 86(Pt 4): 985990.
  • 20
    Cui C, Shi J, Hui L et al. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. J Gen Virol 2002; 83(Pt 11): 27732777.
  • 21
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on preventionand treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007; 120(24): 21592173.
  • 22
    Janssen HL, Van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365(9454): 123129.
  • 23
    Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348(9): 808816.
  • 24
    Chang TT, Gish RG, De Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354(10): 10011010.
  • 25
    Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357(25): 25762588.
  • 26
    Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23): 24422455.
  • 27
    Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351(12): 12061217.
  • 28
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352(26): 26732681.
  • 29
    Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354(10): 10111020.
  • 30
    Yao G, Wang B, Cui Z et al. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl) 1999; 112(5): 387391.
  • 31
    Zeng M, Mao Y, Yao G et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44(1): 108116.
  • 32
    Yao GB, Zhu M, Wang YM et al. [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B]. Zhonghua Nei Ke Za Zhi 2006; 45(11): 891895.
  • 33
    Yao G, Chen C, Lu W et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007; 1(3): 365372.
  • 34
    Hou J, Yin YK, Xu D et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47(2): 447454.
  • 35
    Yao GB, Zhu M, Cui ZY et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009; 10(2): 131137.
  • 36
    Mao Y, Zeng M, Yao G et al. Efficacy and safety of 5 years uninterrupted adefovir dipivoxil 10mg (ADV) in Chinese HBeAg positive chronic hepatitis B (CHB). Hepatol Int 2009; 3(1): P98.
  • 37
    Yao G, Chen C, Lu W et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int 2008; 2(4): 486493.
  • 38
    Yao G, Xu D, Ren H et al. Three years of continuous treatment with entecavir results in high proportions of Chinese nucleoside-naive patients with undetectable HBV DNA: results from studies ETV-023 and -050. J Hepatol 2008; 48: A714.
  • 39
    Jia J, Hou J, Yin Y et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B patients. Hepatol Int 2009; 3: P34.
  • 40
    Lada O, Benhamou Y, Cahour A et al. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9(3): 353363.
  • 41
    Yang H, Qi X, Sabogal A, Miller M, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10(5): 625633.
  • 42
    Sherman M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48(1): 99108.
  • 43
    Chan HL, Wong VW, Chim AM et al. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). Antivir Ther 2008; 13(4): 555562.
  • 44
    Hou J, Sun J, Xie Q et al. A prospective, randomized study of efficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil in treating lamivudine resistance HBeAg positive CHB. J Hepatol 2009; 50(S1): 910.